Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library

Synapse

Volumn 33, Issue 3, 1999, Pages 239-246

  Rothman, Richard B ^a   Baumann, Michael H ^a   Dersch, Christina M ^a   Appel, Jon ^b   Houghten, Richard A ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Cocaine; Combinatorial chemistry; Dopamine; Serotonin; Transporters

Indexed keywords

COCAINE; DOPAMINE TRANSPORTER; HEXAPEPTIDE; LIGAND; PEPTIDE; PEPTIDE LIBRARY; SEROTONIN TRANSPORTER; TPI 6691; TPI 6694; UNCLASSIFIED DRUG; VANOXERINE;

AMINE TRANSPORT; ANIMAL TISSUE; ARTICLE; BINDING SITE; COCAINE DEPENDENCE; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG IDENTIFICATION; MALE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

EID: 0033198025     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(19990901)33:3<239::AID-SYN8>3.0.CO;2-R     Document Type: Article

References (41)

1. Baumann MH, Char GU, de Costa BR, Rice KC, Rothman RB. 1994. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271:1216-1222.
2. Benowitz NL. 1993. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72:3-12 [erratum, Pharmacol Toxicol 1993 72: 343].
3. Bergman J, Madras BK, Johnson SE, Spealman RD. 1989. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155.
4. Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J. 1990. Cocaine abuse among schizophrenic patients. Am J Psych 147:1164-1167.
5. Brauer LH, Goudie AJ, de Wit H. 1997. Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2-13.
6. Bunt G, Galanter M, Lifshutz H, Castaneda R. 1990. Cocaine/"crack" dependence among psychiatric inpatients. Am J Psych 147:1542-1546.
7. Carr GD, Fibiger HC, Phillips AG. 1989. Conditioned place preference as a measure of drug reward. In: Liebman JM, Cooper SJ, editors. The neuropharmacological basis of reward. Oxford: Oxford Science Publication, p 264-317.
8. Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM. 1996. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. J Med Chem 39:1201-1209.
9. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
10. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. 1991. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psych 148:224-230.
11. Dooley CT, Houghten RA. 1993. The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands. Life Sci 52:1509-1517.
12. Freud S. 1884. Uber Coca. Zentralblatt fur die Gesammte Therapie 2:289-314.
13. Houghten RA. 1985. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82:5131-5135.
14. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. 1992. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
15. Koppel G, Dodds C, Houchins B, Hunden D, Johnson D, Owens R, Chaney M, Usdin T, Hoffman B, Brownstein M. 1995. Use of peptide combinatorial libraries in drug design: the identification of a potent serotonin reuptake inhibitor derived from a tripeptide cassette library. Chem Biol 2:483-487.
16. Kuhar MJ, Ritz MC, Boja JW. 1991. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
17. Lowry OH, Rosenbrough NH, Farr AL, Randall PJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. 3H] Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
19. Ohuoha DC, Maxwell JA, Thomson LE, Cadet JL, Rothman RB. 1997. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J Subst Abuse Treat 14:249-258.
20. Paxinos G. 1982. The rat brain in stereotaxic coordinates. New York: Academic Press.
21. Pinilla C, Appel JR, Blanc P, Houghten RA. 1992. Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. Biotechniques 13:901-905.
22. Pitts DK, Marwah J. 1987. Neuropharmacology of cocaine: role of monoaminergic systems [Review]. Monogr Neural Sci 13:34-54.
23. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
24. Ritz MC, Kuhar MJ, George FR. 1992. Molecular mechanisms associated with cocaine effects. Possible relationships with effects of ethanol. Recent Dev Alcohol 10:273-302.
25. Rodbard D, Lenox RH, Wray HL, Ramseth D. 1976. Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin Chem 22:350-358.
26. Ross SB, Renyi AL. 1967. Inhibition of the uptake of tritiated catecholamines by anti-depressants and related compounds. Eur J Pharmacol 2:181-186.
27. Rothman RB. 1990. High affinity dopamine reuptake blockers as potential cocaine antagonists: a strategy for drug development. Life Sci 46:PL17-PL21.
28. Rothman RB. 1994. A review of the effects of dopamimetic agents in humans: implications for medication development. NIDA Res Monogr 145:67-85.
29. Rothman RB, Glowa JR. 1995. A review of the effects of dopaminergic agents on humans, animals and drug seeking behavior, and its implications for medication development: focus on GBR12909. Mol Neurobiol 11:1-19.
30. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci 53:PL267-PL272.
31. Rothman RB, Lewis B, Dersch CM, Xu H, Radesca L, de Costa BR, Rice KC, Kilburn RB, Akunne HC, Pert A. 1993b. Identification of a GBR12935 homolog LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse 14:34-39.
32. 125I]RTI-55. J Pharmacol Exp Ther 270:296-309.
33. 126I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate. Synapse 28:322-338.
34. Scheffel U, Dannals RF, Cline EJ, Ricaurte GA, Carroll FI, Abraham P, Lewin AH, Kuhar MJ. 1992. [123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse 11:134-139.
35. Schneier FR, Siris SG. 1987. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 175:641-652.
36. Sevy S, Kay SR, Opler LA, van Praag HM. 1990. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 178:642-648.
37. Slusher BS, Tiffany CW, Olkowski JL, Jackson PF. 1997. Use of identical assay conditions for cocaine analog binding and dopamine uptake to identify potential cocaine antagonists. Drug Alcohol Depend 48:43-50.
38. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR. 1998. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704.
39. Spealman RD, Madras BK, Bergman J. 1989. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149.
40. Van der Zee P, Roger HS, Gootjes J, Hespe W. 1980. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15:363-370.
41. Wise RA. 1981. Brain dopamine and reward. In: Cooper SJ, editor. Theory in psychopharmacology. London/New York: Academic Press, p 103-122.